Any drug subject to

Section is misbranded unless the manufacturer, packer, or distributor of the drug includes, in all advertisements and other descriptive matter issued or caused to be issued by the manufacturer, packer, or distributor with respect to that drug, a true statement of all of the following: (

a) The established name, printed prominently and in a type at least half as large as that used for any proprietary name of the drug. (

b) The formula showing quantitatively each ingredient of the drug to the extent required for labels under

Section 111355. (

c) The name and place of business of the manufacturer that produced the finished dosage form of the drug, as prescribed by regulations issued by the department. This subdivision applies only to advertisements or descriptive matter issued for drugs manufactured in finished dosage form on or after April 1, 1973. (

d) Such other information, in brief

summary relating to side effects, contraindications, and effectiveness as shall be required by regulations promulgated by the department. Regulations relating to side effects, contraindications, and effectiveness issued pursuant to

Section 502(

n) of the federal act (21 U.S.C. Sec. 352(n)) are the regulations establishing information requirements relating to side effects, contraindications and effectiveness in this state. The department may, by regulation, make other requirements relating to side effects, contraindications, and effectiveness whether or not in accordance with the regulations adopted under the federal act.